Tofacitinib: all 184 studies that test it

Page 2 of 2. Open to participants first (41), then studies with results posted, then the rest; newest registration first within each.

• A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisTerminatedNCT01163253Phase 3Results posted
• A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye DiseaseCompletedNCT01135511Phase 2Results posted
• Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTXCompletedNCT01039688Phase 3Results posted
• Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) InhibitorsCompletedNCT00960440Phase 3Results posted
• A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis MedicationsCompletedNCT00856544Phase 3Results posted
• A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid ArthritisCompletedNCT00853385Phase 3Results posted
• A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background MethotrexateCompletedNCT00847613Phase 3Results posted
• A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid ArthritisCompletedNCT00814307Phase 3Results posted
• A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.CompletedNCT00787202Phase 2Results posted
• A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.CompletedNCT00784719Phase 1/2Results posted
• Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In JapanCompletedNCT00687193Phase 2Results posted
• Topical CP-690,550 For Chronic Plaque PsoriasisCompletedNCT00678561Phase 2Results posted
• Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00678210Phase 2Results posted
• Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In JapanCompletedNCT00661661Phase 3Results posted
• Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant PatientsCompletedNCT00658359Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00615199Phase 2Results posted
• Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in JapanCompletedNCT00603512Phase 2Results posted
• A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid ArthritisCompletedNCT00550446Phase 2Results posted
• Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant PatientsCompletedNCT00483756Phase 2Results posted
• Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid ArthritisCompletedNCT00413699Phase 3Results posted
• Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid ArthritisCompletedNCT00413660Phase 2Results posted
• Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant PatientCompletedNCT00263328Phase 2Results posted
• Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 WeeksCompletedNCT00147498Phase 2Results posted
• A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant PatientsCompletedNCT00106639Phase 2Results posted
• Tofacitinib in the Treatment of IgG4 Related DiseasesCompletedNCT07827469Not applicable
• Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With MethotrexateCompletedNCT07472166Phase 4
• Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of VitiligoActive, not recruitingNCT07044141Phase 1
• Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation StudyCompletedNCT06310057Phase 4
• Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.CompletedNCT06278402Phase 3
• Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia RheumaticaCompletedNCT06172361Phase 3
• Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia AreataCompletedNCT06157905Early Phase 1
• Therapies for Down Syndrome Regression DisorderCompletedNCT05662228Phase 2
• To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 WeeksStatus unknownNCT05606107Phase 4
• Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic DermatitisCompletedNCT05487963Phase 1/2
• Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory MyopathiesStatus unknownNCT05400889Phase 2
• Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic EventsCompletedNCT05313620Phase 4
• Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.Status unknownNCT05246293Phase 2
• Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsCompletedNCT05104723Phase 1/2
• Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's SyndromeStatus unknownNCT05087589Phase 2
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3CompletedNCT04985955Phase 1
• Effect of Tofacitinib in Treating ANCA-associated VasculitisCompletedNCT04973033Not applicable
• Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPAStatus unknownNCT04944524Phase 4
• The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid ArthritisStatus unknownNCT04927000Phase 4
• Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis ManagementActive, not recruitingNCT04925973Phase 2
• Tofacitinib as a GC Sparing Agent for Polymyalgia RheumaticaCompletedNCT04799262Phase 2
• Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK StudyTerminatedNCT04768504Phase 2
• Efficacy and Safety of Tofacitinib in Patients With COVID-19 PneumoniaCompletedNCT04750317Phase 2
• Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisActive, not recruitingNCT04624230Phase 3
• Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA PatientsCompletedNCT04485325Phase 4
• Tofacitinib in Hospitalized Patients With COVID-19 PneumoniaCompletedNCT04469114Phase 3
• Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging StudyCompletedNCT04468425Phase 1
• Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid ArthritisStatus unknownNCT04464642Phase 4
• Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot StudyCompletedNCT04431895Early Phase 1
• Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care TherapyWithdrawnNCT04412252Phase 2
• PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release FormulationCompletedNCT04403776Phase 1
• TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial PneumoniaStatus unknownNCT04390061Phase 2
• TOFAcitinib in SARS-CoV2 PneumoniaStatus unknownNCT04332042Phase 2
• Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung DiseaseTerminatedNCT04311567Phase 4
• Efficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsStatus unknownNCT04299971Phase 4
• Tofacitinib in Depression (TIDE)TerminatedNCT04141904Phase 1/2
• A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.CompletedNCT04111614Phase 1
• Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvementStatus unknownNCT04062695Phase 2
• Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareCompletedNCT03910543Phase 1
• Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy VolunteersCompletedNCT03868072Phase 1
• Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical TrialStatus unknownNCT03738956Phase 2/3
• Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic ArthritisCompletedNCT03736161Phase 3
• Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm DysfunctionActive, not recruitingNCT03681275Phase 2
• Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
• Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in BangladeshStatus unknownNCT03504072Phase 4
• Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)TerminatedNCT03159936Early Phase 1
• Study of Tofacitinib in Refractory DermatomyositisCompletedNCT03002649Phase 1
• An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural PerspectiveCompletedNCT02566967Phase 3
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus ErythematosusCompletedNCT02535689Phase 1
• Tofacitinib Bioequivalence Study Comparing Tablets And CapsulesCompletedNCT01599377Phase 1
• A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy VolunteersCompletedNCT01499004Phase 1
• A Study Of Tasocitinib In Dry Eye SubjectsWithdrawnNCT01226680Phase 2
• Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy VolunteersCompletedNCT01204112Phase 1
• Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy VolunteersCompletedNCT01185184Phase 1
• A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet FormCompletedNCT01143805Phase 1
• CP-690,550 Pharmacokinetics In Healthy Chinese SubjectsCompletedNCT01101919Phase 1
• A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product TestersCompletedNCT01023100Phase 1
• A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT00969813Phase 1
• Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant PatientsWithdrawnNCT00556257Phase 2

← Tofacitinib overview